8-KLeadership ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Nov 5, 2012)

Filed November 5, 2012For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) announced the departure of Joan E. Miller, Senior Vice President of Pathology and Neurology, effective October 31, 2012. This departure is part of a broader management restructuring initiative by the company, intended to improve operational efficiency and stimulate growth. Investors should note that Dr. Miller's exit is framed as a strategic move rather than a performance issue, aligning with the company's stated goals for operational excellence and growth restoration. In connection with her departure, Dr. Miller will receive benefits under the company's Executive Officer Severance Plan. Additionally, she has entered into a consulting agreement with Quest Diagnostics for a six-month period following her termination, for which she will be compensated $209,496. This ongoing engagement suggests a continued, albeit advisory, relationship during a crucial transition period for the company's leadership and strategic direction.

Key Highlights

  • 1Departure of Joan E. Miller, Senior Vice President, Pathology and Neurology, effective October 31, 2012.
  • 2Departure is part of a management restructuring aimed at operational excellence and restoring growth.
  • 3Dr. Miller is eligible for benefits under the Company's Executive Officer Severance Plan.
  • 4Dr. Miller will provide consulting services for six months post-termination.
  • 5Compensation for consulting services is $209,496.
  • 6Consulting agreement filed as Exhibit 10.1 to the 8-K.

Frequently Asked Questions

Joan E. Miller's departure was in connection with the company's management restructuring, which is aimed at driving operational excellence and restoring growth.

Dr. Miller is entitled to benefits under the Company's Executive Officer Severance Plan as a Schedule A participant.

Yes, Dr. Miller has agreed to provide consulting services to the Company for a six-month period following her termination of employment and will be compensated $209,496 for these services.

The consulting agreement indicates a continued, albeit advisory, involvement of Dr. Miller during a period of management transition. This could provide continuity and leverage her expertise as the company implements its restructuring plan.